Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-lactam dose optimization in adults with febrile neutropenia
ACTRN12615000086561Phase 2Completed
- Sponsor
- NRC Human Health Therapeutics
- Start
- Mar 2014
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of piperacillin + tazobactam, cefepime and meropenem in febrile neutropenia (FN) (2 arms), sponsored by NRC Human Health Therapeutics. Primary endpoint: Attainment of pharmacokinetic/pharmacodynamic target. Started Mar 2014; status: completed.
02
Drugs
piperacillin + tazobactamcefepimemeropenem
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on ACTRN12615000086561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000086561.